Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03584464 · ClinicalTrials.gov registry record · NA
RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)
A NA study, sponsored by Medtronic Vascular.
- Completed
- Registry status
- NA
- Development phase
- 205
- Enrollment target
NCT03584464: Completed NA study, sponsored by Medtronic Vascular.
NCT03584464 is a NA study that has completed, run by Medtronic Vascular. The registered enrollment target is 205 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03584464, a NA study, has completed, sponsored by Medtronic Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 205 participants
- Enrollment target
Study Summary
To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population. To collect data on the safety and efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in bifurcated lesions.
Primary Outcome
Target Vessel Failure (TVF) defined as cardiac death, target vessel myocardial infarction, or clinically-driven target vessel revascularization by percutaneous or surgical methods.
Interventions
- DEVICE Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2018-05-14 |
| Est. Completion | 2022-09-28 |
| Phase | NA |
What the finished NCT03584464 record still lists
NCT03584464 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System is the first listed.
NCT03584464 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03584464 about?
NCT03584464 is a clinical study titled "RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)". To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population. To collect data on the safety and efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in bifurcated lesions.
What is the current status of trial NCT03584464?
This trial is currently completed. It is a NA study. The enrollment target is 205 participants. The study started on 2018-05-14. Estimated completion is 2022-09-28.
What interventions are being tested in trial NCT03584464?
The interventions under investigation include: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System (DEVICE).
Who is sponsoring clinical trial NCT03584464?
This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03584464's enrollment target sits among peer trials
205 499th of 2000 higher than 1,501 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05134857 · 205 participants · Phase 2
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
- NCT05181891 · 205 participants · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI